Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Farage slams British prime minister for ‘extraordinary’ lack...
GOP senators say Trump’s strikes ‘significantly degraded’ Iran...
Trump tells Starmer aircraft carriers no longer needed...
King Charles to address ‘increasing pressures of conflict’...
‘Loud bang,’ damage reported at US Embassy in...
Iran’s last line of resistance holds back —...
State Department defends ‘proactive’ evacuation efforts against Dems’...
Cartels fear US retaliation as Trump-era pressure reshapes...
Trump vows block on signing new laws until...
Trump warns Iran’s new leader won’t ‘last long’...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

FDA chief counsel who defended abortion pill under Biden resigns 2 days into job

by admin March 13, 2025
March 13, 2025
FDA chief counsel who defended abortion pill under Biden resigns 2 days into job

The Food and Drug Administration’s (FDA) top lawyer, who was appointed to the position just this week, has resigned, according to a Thursday morning post on X.

‘Hilary K. Perkins has resigned from her position as Chief Counsel of FDA, effectively immediately,’ the FDA’s official X account posted.  

Perkins – a former assistant director under Biden’s Department of Justice (DOJ) in the consumer protection agency – was selected on Tuesday by acting general Sean Keveney in the Department of Health and Human Services (HHS) as part of a ‘reorganization’ effort by the department, according to an HHS news release.

She previously defended abortion pill access in a high-profile case under Biden’s DOJ, and HHS officials were reportedly unhappy with the decision to appoint Perkins but were overruled by White House officials, according to a report from Axios this week.

‘We’ve been able to recruit higher quality personnel to HHS than in any time in its history,’ HHS Secretary Robert F. Kennedy, Jr., said in a statement Tuesday at the announcement of Perkins’ assignment on Tuesday. ‘These are individuals who will return the agency to gold-standard science, evidence-based medicine, and recalibrate its trajectory toward public health rather than industry profiteering.’

Fox News Digital has reached out to the HHS and FDA for comment.

This is a breaking story, check back for updates.

This post appeared first on FOX NEWS

previous post
The Hitchhiker’s Guide to where we stand to avoid a government shutdown
next post
Senate Republicans coin ‘Schumer shutdown’ ahead of critical vote on Trump spending bill

You may also like

FBI director nominee Kash Patel broke hostage rescue...

January 28, 2025

Supreme Court to hear case on LGBTQ-themed storybooks...

April 22, 2025

Tired of Ukraine? Remember South Vietnam

December 3, 2024

China ramps up military ‘rehearsals’ around Taiwan, outstrips...

April 11, 2025

WINSTON MARSHALL: A British rock star’s view of...

November 16, 2024

Qatar agrees to kick Hamas out of Doha...

November 9, 2024

Gabbard says Comey should be ‘put behind bars’...

May 16, 2025

GREGG JARRETT: Biden, the ‘marionette president; and the case...

June 5, 2025

Kamala Harris should prosecute Big Pharma, not bail...

October 7, 2024

Senate Democrats push Obamacare subsidy vote ‘designed to...

December 8, 2025

Recent Posts

  • Farage slams British prime minister for ‘extraordinary’ lack of support for Trump’s Iran strikes
  • GOP senators say Trump’s strikes ‘significantly degraded’ Iran but emphasize attacks not ‘forever wars’
  • Trump tells Starmer aircraft carriers no longer needed in Mideast, accuses him of joining war US ‘already won’
  • King Charles to address ‘increasing pressures of conflict’ in speech as Trump criticizes British PM on Iran
  • ‘Loud bang,’ damage reported at US Embassy in Norway; police investigating

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (981)
    • Investing (4,282)
    • Politics (5,172)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 Sightful Invest. All Rights Reserved.